Int J STD AIDS. 2014 Jan 27.
Falasca K, Ucciferri C, Di Nicola M, Vignale F, Di Biase J, Vecchiet J.
Background High incidence of 25OH vitamin D deficiency has been observed in HIV-infected subjects.
Objective The objective of this study was to evaluate the effect of cholecalciferol administration on serum 25OH vitamin D levels in HIV-infected patients.
Methods This prospective cohort study included 153 HIV + subjects; 47 were treated with 300,000 IU intramuscular cholecalciferol, 67 with 25,000 IU oral cholecalciferol monthly, while the remaining 39 did not receive any treatment.
Results The group treated
- orally had an increase of serum 25OH vitamin D concentration, changing from 15.7 ± 12.2 ng/mL to 27.4 ± 11.6 ng/mL after 10 months (T10).
The group treated with
- intramuscular supplementation had an improvement, changing from 18.5 ± 10.5 ng/mL to 32.9.0 ± 12.2 ng/mL at T10.
One-way repeated measures analysis of variance indicated a significant difference for 25OH vitamin D variation (p = 0.002) among the three groups.
A significant effect of time (p < 0.001) and group × time interaction (p < 0.001) was found; at T10, 25OH vitamin D values were significantly higher in the oral and intramuscular groups with respect to the control group.
Conclusions Our findings showed that the supplementation with cholecalciferol in patients with HIV-infection improved 25OH vitamin D serum levels, and suggest that the two types of administration are equivalent, but are insufficient to severe forms of hypovitaminosis.
- Megadose injection of up to 600,000 IU vitamin D3 every three months for adolescents - April 2010
- Reduced depression with single 300,000 IU injection of vitamin D – RCT June 2013
- Review of Vitamin D (including free, frequency, injection, how much.) – Sept 2013
- 300,000 IU loading dose of vitamin D3 stopped gestational diabetes in RCT – Oct 2011